Ted Witek, DrPH, Appointed as
Chairman of the Board
Steve Stefano and Harry Levy, M.D., Appointed as Directors
TORONTO, Jan. 10, 2017 /PRNewswire/ -- Ehave, Inc.
(OTCQB: EHVVF), a healthcare company dedicated to empowering the
mental health community with next-generation digital solutions,
today announced the appointment of three members to its Board of
Directors. Ted Witek, DrPH, Chief
Scientific Officer at Innoviva (Nasdaq: INVA); Steve Stefano, Managing Director at Ashfield
Market Access; and Harry Levy, M.D.,
Chief Executive Officer of interMDnet Corporation, will join
Ehave's Board effective today. Scott
Woodrow, founder and former Chairman of the Board at Ehave,
has been reappointed as a Director.
"The appointment of Ted as our Chairman of the Board and Steve
and Harry as Directors will provide Ehave with guidance from some
of the most successful people in the healthcare industry," said
Prateek Dwivedi, President and CEO
of Ehave. "Ted's long and diverse career in large pharma,
small biotech and healthcare public policy will help us to execute
on our strategy to develop and grow Ehave Connect through the
establishment of partnerships with a variety of companies in mental
healthcare. His involvement and thought leadership validates the
significant potential of our company."
Prateek Dwivedi continued, "In
addition, Steve's depth of knowledge and long-term relationships
with payors, including pharmacy benefit managers (PBMs), national
insurers, regional healthcare plans and state Medicaid
associations, will be extremely valuable as we navigate the
healthcare coverage landscape in the U.S. leading up to the
commercialization of Ehave Connect. Furthermore, Harry's
experience creating efficient digital platforms that enable
e-learning for physicians will allow us to optimize the design of
our digital platform to ensure it meets the needs of mental health
professionals. We thank Scott
Woodrow for the time he spent as Chairman of the Board as
well as David Stefansky and
Jesse Kaplan for the contributions
they made to Ehave as previous Directors of our Board."
Ted Witek, DrPH,
Chairman
Dr. Ted Witek is a healthcare
executive and scholar based in Toronto and Lisbon. He currently serves as the Chief
Scientific Officer of Innoviva (Nasdaq: INVA). He is also appointed
a Senior Fellow at the Institute of Health Policy, Management, and
Evaluation of The University of Toronto
and Professor at the Dalla Lana School of Public Health and Faculty
of Pharmacy.
Prior to joining Innoviva, Dr. Witek served as President and
Chief Executive Officer of Boehringer Ingelheim in Canada and in Portugal. Joining Boehringer in 1992, Dr.
Witek held a number of positions of increasing responsibility,
including leading the global clinical development and launch of
several respiratory products, most notably Spiriva®. Dr. Witek led
the Respiratory and Immunology clinical research groups in the U.S.
and served as the Boehringer Co-chair of the Joint Operating
Committee with Pfizer in their global alliance. During his tenure
in Canada, Dr. Witek served on the
Board of Directors at Rx&D, Canada's National Association for
Research-Based Pharmaceutical Companies, chairing its Heath
Technology Assessment and Public Affairs Committees. He also served
more than 10 years on the Drug/Device Discovery and Development
Committee of the American Thoracic Society, serving as Chairman
from 2010 to 2012. He currently serves on the Ontario Heath
Innovation Council. Dr. Witek holds a doctorate of public health
from Columbia University, an M.P.H.
from Yale University, and an MBA from
Henley Management College.
Steve Stefano,
Director
Steve Stefano is a seasoned
pharmaceutical executive and entrepreneur with more than 30 years
of relevant industry experience. Mr. Stefano currently serves as
Managing Director of Ashfield Market Access, a subsidiary of United
Drug Group, a multi-national corporation based in Dublin, Ireland, that provides outsourced
commercial and medical solutions to biopharmaceutical companies.
Ashfield Market Access is a consulting organization that
specializes in market research, market strategies, and account
management for payer reimbursement and retail distribution in the
U.S. commercial market. Prior to joining the Ashfield Market
Access, Mr. Stefano founded and served as Managing Partner of
SynopiaRx, a consulting firm specializing in U.S. payer
reimbursement and retail distribution. SynopiaRx was acquired by
United Drug Group in 2012.
From 1986 to 2009, Mr. Stefano held various roles of increased
responsibility at Glaxo, GlaxoWellcome, and GlaxoSmithKline (GSK),
within its commercial organizations. From 1986 to 2009, Mr. Stefano
led GSK's U.S. Payer Markets Divisions. From 2001 to 2008, he led
GSK's Neurohealth Division, and organically grew the division's
sales from $300 million to
$2.6 billion in seven years. Mr.
Stefano also spearheaded the acquisition of several critical and
strategic in-licensed medicines for GSK, including Horizant®,
Dynastat®, and Potiga®, as well as the acquisition of Reliant
Pharmaceuticals.
Mr. Stefano served on the Board of Directors for Valeant
Pharmaceuticals (2008-2010), Teamm Pharmaceuticals (2001-2004), and
The Jimmy V Celebrity Golf Classic (2002-2009). He has been a
frequent guest lecturer at the Duke Fuqua
School of Business and at the University of Pennsylvania Wharton School of
Business. He is a graduate of Saint Joseph's
University.
Harry Levy, M.D.,
Director
Dr. Harry Levy, who is the
Founder and CEO of interMDnet Corporation, which for the past 20
years in partnership with the Albert Einstein College of Medicine
in New York and academic
professors from 15 other U.S. medical schools, has pioneered the
design and distribution of e-learning for physicians, allied
medical professionals, and health consumers. Among its many
clinical offerings across various digital platforms, interMDnet
created innovative "medutainment," real-time, competitive
educational games which motivate physicians to adopt new clinical
guidelines and protocols.
Prior to founding interMDnet, Dr. Levy was the research director
of Health Opinion Research, Inc., where he led the development of
"video interactive patients," a research tool designed to
prospectively assess actual physician-patient practice behavior.
Dr. Levy received his A.B. degree from Columbia University, his M.D. from New York University, post-doctoral training in
community and preventive medicine at the Mount Sinai School of
Medicine in New York, where he was
later a fellow and junior faculty member, and his M.P.H. from
Yale.
About Ehave, Inc.
Ehave is empowering the mental healthcare community with
next-generation, data-rich patient management, assessment, and
remediation tools. With Ehave Connect, Ehave's cloud-based software
platform, clinicians can make better-informed, individualized
treatment decisions across teams and disciplines while keeping
patients informed and engaged throughout their mental healthcare
journey. Ehave Connect offers a powerful set of core features that
integrate seamlessly with a growing selection of tools and
applications developed by Ehave and its leading partners. Ehave is
launching several digital applications under its MegaTeam brand for
the assessment and remediation of ADHD, with pilot studies now
underway at the Hospital for Sick Children (SickKids). Ehave is
headquartered in Toronto's
Discovery District, a hub of healthcare, innovation, and technology
in Toronto, Canada. For more
information, visit https://www.ehave.com/
Forward-Looking Statement Disclaimer
This press release contains "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995. Such statements may be preceded by the words "intends,"
"may," "will," "plans," "expects," "anticipates," "projects,"
"predicts," "estimates," "aims," "believes," "hopes," "potential"
or similar words. Forward-looking statements are based on certain
assumptions and are subject to various known and unknown risks and
uncertainties, many of which are beyond the Company's control, and
cannot be predicted or quantified and consequently, actual results
may differ materially from those expressed or implied by such
forward-looking statements: (i) the initiation, timing, progress
and results of the Company's research, manufacturing and other
development efforts; (ii) the Company's ability to advance its
products to successfully complete development and
commercialization; (iii) the manufacturing, development,
commercialization, and market acceptance of the Company's products;
(iv) the lack of sufficient funding to finance the product
development and business operations; (v) competitive companies and
technologies within the Company's industry and introduction of
competing products; (vi) the Company's ability to establish and
maintain corporate collaborations; (vii) loss of key management
personnel; (viii) the scope of protection the Company is able to
establish and maintain for intellectual property rights covering
its products and its ability to operate its business without
infringing the intellectual property rights of others; (ix)
potential failure to comply with applicable health information
privacy and security laws and other state and federal privacy and
security laws; and (x) the difficulty of predicting actions of the
USA FDA and its regulations. All
forward-looking statements included in this press release are made
only as of the date of this press release. The Company assumes no
obligation to update any written or oral forward-looking statement
unless required by law. More detailed information about the Company
and the risk factors that may affect the realization of
forward-looking statements is contained under the heading "Risk
Factors" in Ehave, Inc.'s Registration Statement on Form F-1 filed
with the Securities and Exchange Commission (SEC) on September 24, 2015, as amended, which is
available on the SEC's website, http://www.sec.gov
Contact
Tiberend Strategic Advisors, Inc.
Joshua Drumm, Ph.D.
(investors)
jdrumm@tiberend.com; (212) 375-2664
Claire LaCagnina
(media)
clacagnina@tiberend.com; (212) 375-2686
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/ehave-inc-appoints-new-members-to-its-board-of-directors-300388503.html
SOURCE Ehave, Inc.